The Rho Exchange Factors Vav2 and Vav3 Favor Skin Tumor Initiation and Promotion by Engaging Extracellular Signaling Loops by Menacho-Márquez, Mauricio et al.
The Rho Exchange Factors Vav2 and Vav3 Favor Skin
Tumor Initiation and Promotion by Engaging
Extracellular Signaling Loops
Mauricio Menacho-Ma´rquez1,2, Ramo´n Garcı´a-Escudero3, Virginia Ojeda1,2, Antonio Abad1,2,
Pilar Delgado4, Clotilde Costa3, Sergio Ruiz1,2, Balbino Alarco´n4, Jesu´s M. Paramio3, Xose´ R. Bustelo1,2*
1 Centro de Investigacio´n del Ca´ncer, Consejo Superior de Investigaciones Cientı´ficas (CSIC)–University of Salamanca, Salamanca, Spain, 2 Instituto de Biologı´a Molecular y
Celular del Ca´ncer, Consejo Superior de Investigaciones Cientı´ficas (CSIC)–University of Salamanca, Salamanca, Spain, 3 Molecular Oncology Unit, Centro de
Investigaciones Energe´ticas, Medioambientales y Tecnolo´gicas, Madrid, Spain, 4 Centro de Biologı´a Molecular ‘‘Severo Ochoa,’’ CSIC–Madrid Autonomous University,
Madrid, Spain
Abstract
The catalytic activity of GDP/GTP exchange factors (GEFs) is considered critical to maintain the typically high activity of Rho
GTPases found in cancer cells. However, the large number of them has made it difficult to pinpoint those playing proactive,
nonredundant roles in tumors. In this work, we have investigated whether GEFs of the Vav subfamily exert such specific
roles in skin cancer. Using genetically engineered mice, we show here that Vav2 and Vav3 favor cooperatively the initiation
and promotion phases of skin tumors. Transcriptomal profiling and signaling experiments indicate such function is linked to
the engagement of, and subsequent participation in, keratinocyte-based autocrine/paracrine programs that promote
epidermal proliferation and recruitment of pro-inflammatory cells. This is a pathology-restricted mechanism because the
loss of Vav proteins does not cause alterations in epidermal homeostasis. These results reveal a previously unknown Rho
GEF-dependent pro-tumorigenic mechanism that influences the biology of cancer cells and their microenvironment. They
also suggest that anti-Vav therapies may be of potential interest in skin tumor prevention and/or treatment.
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Introduction
Rho guanosine nucleotide exchange factors (Rho GEFs)
promote the transition of Rho family GTP hydrolases (GTPases)
from the inactive (GDP bound) to the active (GTP bound) state
during signal transduction [1,2]. These enzymes can be subdivided
into the Dbl-homology (DH) and the Dedicator of Cytokinesis
(Dock) families based on the catalytic domain utilized for the
GDP/GTP exchange reaction. A common feature of these two
families is their extreme diversity because, in mammals, they are
composed of 54 and 11 members, respectively. These family
members vary widely in terms of catalytic specificity, presence of
regulatory and effector domains, mechanism of activation, and
expression patterns. As a consequence, they are key elements to
adapt the activation of Rho GTPases to specific cell types,
membrane receptors, or subcellular localizations [1,2]. Rho GEFs
have been traditionally regarded as important for tumorigenesis
and, thereby, as potential drug targets [3]. However, the large
number of Rho GEFs and their regulatory complexity have made
it difficult to identify which ones were the most important for the
development and/or progression of specific tumors. Inferences
from sequencing data have not been useful in this case, because
their genes seldom undergo mutations in cancer cells [3]. The use
of animal models in this functional context has been also rather
limited. However, the few studies available do support the idea
that these enzymes have pro-tumorigenic functions. Thus, the T-
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cell lymphoma invasion and metastasis-inducing protein 1 (Tiam1,
ID number: 21844) has been shown to be important for both
cutaneous squamous and colorectal [4,5] tumors. The adenoma-
tous polyposis coli-stimulated exchange factor 1 (Asef1, ID
number: 226970) and Asef2 (ID number: 219140) proteins have
been linked to colorectal cancer [6]. Finally, Vav3 (ID number:
57257) and phosphatidylinositol 3,4,5-triphosphate-dependent
Rac exchanger 1 (P-Rex1, ID number: 277360) are involved in
the development of p190Brc/Abl-driven acute lymphoblastic
leukemia and melanoma, respectively [7,8].
Vav proteins exemplify well the complexity existing in the large
Rho GEF family. Thus, this subfamily has three members in
vertebrates (Vav1 [ID number: 22324], Vav2 [ID number:
22325], Vav3) that display overlapping but not identical expres-
sion patterns. They all share similar structures that encompass a
complex array of regulatory, catalytic, and protein–protein
interaction domains [9]. These domains enable them to interact
with and become activated by receptors with either intrinsic or
associated tyrosine kinase activity, activate GDP/GTP exchange
on Rho GTPases, and in addition, engage parallel routes in
GTPase-independent manners [9–17]. The physiological role of
Vav proteins in the immune, nervous, and cardiovascular systems
are now well established thanks to the use of genetically engineered
mice [9,18–25]. By contrast, the genetic analysis of the role of
these proteins in cancer has been restricted so far to acute
lymphoblastic leukemia and polyomavirus middle T-antigen-
induced breast cancer. These studies have revealed that Vav3
and Vav2 plus Vav3 were required for the development of each of
those tumors, respectively [7,17].
In the present work, we aimed at expanding the spectrum of
Vav family-dependent tumors by focusing our attention on
cutaneous squamous tumors (CSTs), the second most frequent
type of skin cancer worldwide [26]. To this end, we decided to use
Vav family knockout mice to evaluate the role of these proteins in
the development of 7,12-dimethylben[a]antracene (DMBA)/12-
O-tetradecanoylphorbol-13-acetate (TPA)- and DMBA/DMBA-
triggered skin tumors. In the former model, a single topic
administration of DMBA induces oncogenic mutations (Q61L)
in the HRas locus (ID number: 15461) in a small pool of
keratinocytes (initiation phase). Subsequent serial topic applica-
tions of TPA are then applied to expand this pool of transformed
keratinocytes to generate papillomas (promotion phase) and,
depending on the genetic background of mice, cutaneous
squamous cell carcinomas (cSCCs) (progression phase). Such
pro-tumorigenic effect is mediated by the stimulation of intracel-
lular signaling cascades in the initiated keratinocytes and, in
addition, through autocrine/paracrine-based crosstalk between
cancer and tumor-associated stromal cells that ultimately favor the
expansion of the initial pool of transformed keratinocytes [27–30].
The latter model uses serial topic applications of DMBA that
increase the frequency of cSCC development at the end of the
carcinogenic protocol. We selected these models for our experi-
ments because: (i) they are known to be Rac1- (ID number: 19353)
and Tiam1-dependent [4,31]; (ii) high levels of two Vav family
proteins and a large number of additional Rho GEFs are present
in normal and tumoral skin (see Figure S1), thus making a perfect
working model to address intra-GEF family redundancies in a
tumorigenic context; and (iii) they are compatible with the analysis
of the role of the proteins under study in the tumor initiation,
promotion, and progression phases [28]. Using this strategy, we
have unveiled a Vav2/Vav3-dependent and cancer-specific
autocrine/paracrine program that contributes to the initiation
and promotion phases of skin tumors.
Results
Vav2 and Vav3 Proteins Are Essential for Skin
Tumorigenesis
Expression analyses indicated that mouse papillomas and
cSCCs expressed large numbers of Rho GEFs, including Vav2
and Vav3 (Figure S1). To assess if these two Vav family proteins
played nonredundant roles with other Rho GEFs in the skin, we
used compound Vav22/2;Vav32/2 mice to evaluate the impact of
the systemic inactivation of these two proteins in both epidermal
maintenance and tumorigenesis. Unlike the case of Rac12/2 mice
[32–34], we could not find any defect in skin development,
histological structure, or self-renewal in those mice regardless of
the genetic background used (Figure S2 and unpublished data).
Wild-type-like parameters were also found in triple Vav12/2;Vav22/2;
Vav32/2 C57BL/10 mice, indicating that the lack of an epidermal
phenotype was not due to functional compensation events by Vav1
(unpublished data). Hence, other Rho/Rac GEFs must be in charge
of stimulating Rac1 in skin stem cells and keratinocytes under
physiological conditions. By contrast, we observed that Vav22/2;
Vav32/2 FVB mice displayed lower kinetics of tumor development
(Figure 1A), a <5-fold reduction in the total number of tumors
developed per mouse (Figure 1B,C), and 10-fold lower levels of
carcinoma in situ (Table S1) when subjected to the two-step
DMBA/TPA carcinogenic method. This effect was independent
of the mouse genetic background, because C57Bl/10 Vav22/2;
Vav32/2 mice also showed statistically significant reductions in tumor
burden when compared to control animals (Figure 1D–F). Vav22/2;
Vav32/2 FVB mice also displayed lower kinetics of tumor
development (Figure 1G), a 2-fold reduction in tumor burden per
mouse (Figure 1H,I), and a decrease in the percentage of cSCC
development (Table S2) when subjected to the complete DMBA/
DMBA tumorigenic method. Taken together, these results indicate
that Vav2 and Vav3 play important roles in CST development but
not in normal epithelial development and homeostasis.
Vav Proteins Are Important for the Initiation Phase of
Skin Tumorigenesis
The lower tumor burden observed in DMBA/DMBA-treated
Vav22/2;Vav32/2 mice indicated that Vav proteins may have
Author Summary
GDP/GTP exchange factors (GEFs) involved in Rho GTPase
activation have been traditionally considered as potential
anticancer drug targets. However, little is known about the
best GEFs to inhibit in different tumor types, the pro-
tumorigenic programs that they regulate, and the collat-
eral effects that inactivation may induce in healthy tissues.
Here, we investigate this issue in HRas-dependent skin
tumors using genetic techniques. Despite the large
number of Rho GEFs present in both normal and tumoral
epidermis, we demonstrate that the co-expression of the
exchange factors Vav2 and Vav3 is critical for the
development of this tumor type. We also identify a
previously unknown Vav-dependent autocrine/paracrine
program that favors keratinocyte survival/proliferation and
the formation of an inflammatory state during the
initiation and promotion phases of this tumor. Finally,
our results indicate that inactivation of Vav proteins is
innocuous for the homeostasis of normal epidermis. Taken
together, these results imply that Vav protein-based
therapies may be of interest for skin tumor prevention
and/or treatment.
Role of Vav Proteins in HRas-Dependent Skin Tumors
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direct roles during the initiation phase of CSTs. To investigate this
possibility, we analyzed the short-term response of the epidermis of
wild type and Vav22/2;Vav32/2 mice to DMBA (Figure 2A).
Using immunostaining with antibodies to the cleaved fragment of
caspase 3, we observed that DMBA induced <2-fold higher
apoptotic cell numbers in the epidermis of Vav22/2;Vav32/2 mice
than in controls (Figure 2B,C). This was not due to enhanced
absorption and/or metabolization of the carcinogen, because
immunohistochemistry experiments with antibodies to phospho-
histone H2AX (ID number: 15270) indicated that the DMBA
treatment triggered similar levels of DNA double-strand breaks in
mice of both genotypes (Figure 2D,E). We also found that primary
Vav22/2;Vav32/2 keratinocytes were more susceptible to pro-
grammed cell death upon DMBA treatment or serum starvation in
tissue culture, suggesting that the defects detected in vivo were
keratinocyte autonomous (Figure 2F). This was a stimulus-
dependent defect, because wild-type and mutant keratinocytes
displayed similar cell death rates when challenged with other pro-
Figure 1. Expression of Vav2 and Vav3 is important for CST development. (A, B) Incidence (A) and number (B) of tumors in DMBA/TPA-
treated FVB mice of indicated genotypes. The differences in tumor incidence up to week 10 (A) and in tumor number (B) were statistically significant
(p#0.001, n= 15 animals per genotype in each experiment). (C) Example of animals subjected to the above treatments for 16 wk. (D, E) Incidence (D)
and number (E) of tumors in DMBA/TPA-treated C57BL/10 mice of indicated genotypes. The differences in tumor incidence up to week 15 (D) and in
tumor number (E) were statistically significant (p#0.001, n= 15 animals per genotype in each experiment). (F) Example of C57BL/10 mice of the
indicated genotypes that were subjected to the above treatment for 16 wk. (G, H) Incidence (G) and number (H) of tumors in DMBA/DMBA-treated
FVB mice of indicated genotypes. The differences in tumor incidence up to week 13 (G) and in tumor number (H) were statistically significant
(p#0.001, n= 15 animals per genotype in each experiment). (I) Example of animals subjected to the above treatments for 16 wk.
doi:10.1371/journal.pbio.1001615.g001
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Figure 2. Vav proteins participate in the initiation phase of skin tumors. (A) Scheme of these experiments. (B, C) Example (B; scale bar,
100 mm) and quantification (C) of apoptotic cells found in the epidermis of mice of the indicated genotypes 24 h upon the application of DMBA
Role of Vav Proteins in HRas-Dependent Skin Tumors
PLOS Biology | www.plosbiology.org 4 July 2013 | Volume 11 | Issue 7 | e1001615
apoptotic agents such as radiomimetic (bleomycin) and endoplas-
mic reticulum stress-inducing (dithiothreitol) drugs (Figure 2F).
The ectopic expression of either HA-tagged Vav2 or Myc-tagged
Vav3, but not of the control green fluorescent protein (GFP, ID
number: P42212), restored wild-type-like apoptotic rates in both
DMBA-treated and serum-starved Vav22/2;Vav32/2 keratino-
cytes (Figure 2G,H), further indicating that this survival defect was
a direct effect of the Vav2;Vav3 gene deficiency in keratinocytes.
Vav Proteins Are Important for the Promotion Phase of
Skin Tumorigenesis
We hypothesized that Vav proteins could be also involved in the
TPA-dependent promotion phase of skin tumors, an idea
consistent with our prior observations indicating that the effect
of the double Vav2;Vav3 gene deficiency in the reduction of tumor
burden was significantly more conspicuous in DMBA/TPA- than
in DMBA/DMBA-treated mice (Figure 1; compare panels B and
H). To investigate this possibility, we evaluated the short-term
proliferative and inflammatory reaction induced by TPA in the
skin of control and Vav22/2;Vav32/2 mice (Figure 3A). The TPA-
induced proliferative response of the epidermis was severely
attenuated in the absence of these two proteins, as demonstrated
by the limited hyperplasia (Figure 3B,C) and the low levels of
BrdU incorporation into keratinocytes (Figure 3D) detected in the
epidermal layers of TPA-treated Vav22/2;Vav32/2 mice. In vivo
BrdU pulse-chase experiments indicated that those proliferative
defects were associated with delayed kinetics and a reduced
efficiency in the G1/S phase transition induced by TPA in the
mutant keratinocytes (Figure 3E). Consistent with this, immuno-
blot analyses using total cellular extracts obtained from the
epidermis of TPA-treated mice showed that the activation
(extracellular regulated kinase, [Erk, ID numbers: 26417,
26413], signal transduction and activator of transcription 3 [Stat3,
ID number: 20848]) or abundance (cyclin E, ID number: 12447)
of proteins involved in such cell cycle transition did not take place
efficiently in Vav22/2;Vav32/2 mice (Figure 3F). Furthermore, we
observed that the dermis of these animals did not show any sign of
neutrophil infiltration (Figure 3G,H) or edema-associated thick-
ening (Figure 3G,I), indicating that the inflammatory response that
takes places during the tumor promotion phase is totally abated in
the absence of Vav proteins.
The lack of an inflammatory response led us to explore the
potential contribution of Vav22/2;Vav32/2 inflammatory cells to
the proliferative defects found in the epidermis of Vav22/2;Vav32/2
mice. We observed that such defects still persisted in Vav22/2;
Vav32/2 C57BL/10 mice carrying a wild-type C57BL/6-Ly5.1
hematopoietic system (Figure 4A–C), ruling out the possibility that
the defective proliferation of the epidermis of the knockout animals
could be an indirect consequence of dysfunctional hematopoietic
cells. In agreement with those results, we also found that the grafting
of Vav22/2;Vav32/2 C57BL/10 bone marrow cells into lethally
irradiated wild-type C57BL/6-Ly5.1 mice did not have any
detectable effect on the responsiveness of the epidermis of host
animals to TPA (Figure 4D–F).
Vav Proteins Regulate a Mitogenic, Protein Kinase C/Fyn-
Dependent Route in Keratinocytes
To further assess the keratinocyte autonomous nature of the
proliferative defects found in the epidermis of Vav22/2;Vav32/2
mice, we evaluated the proliferative response of wild-type and
Vav2;Vav3-deficient primary keratinocytes to TPA in cell culture.
In agreement with the in vivo data, we observed that quiescent
Vav22/2;Vav32/2 keratinocytes incorporated less efficiently the S
phase marker 5-ethynyl-29-deoxyuridine (EdU) than their wild-
type counterparts upon TPA stimulation (Figure 5A). This was a
TPA-specific defect, because Vav22/2;Vav32/2 keratinocytes
showed normal cell cycle progression when stimulated with
complete growth media (Figure 5A). Western blot and GTPase-
linked immunosorbent (G-LISA) assays revealed that the Vav2;-
Vav3 gene deficiency was associated to reduced amounts of
activation of Erk (Figure 5B, upper panel), Stat3 (Figure 5B, third
panel from top), and Rac1 (Figure 5C, upper panel) in TPA-
stimulated cells. It also reduced the basal levels of RhoA (ID
number: 11848) activation in nonstimutated cells and, in addition,
eliminated the inactivation of RhoA that was typically observed in
TPA-stimulated wild-type keratinocytes (Figure 5C, lower panel).
Normal levels of Erk and Rac1 activation were observed upon
overexpression of HA-tagged Vav2 (Figure S3A,C) or Myc-tagged
Vav3 in Vav2;Vav3-deficient keratinocytes (Figure S3B,C), thus
confirming that those defects were directly due to the Vav2;Vav3
gene deficiency. Furthermore, and consistent with the TPA-
specific deficiency of the cell cycle transitions, we observed that
those signaling responses were normal when Vav22/2;
Vav32/2 keratinocytes were stimulated with either serum or
synthetic CnT07 media (Figure 5D,E).
We surmised that a tyrosine kinase had to be involved in this
process, because Vav proteins cannot be activated by direct TPA/
diacylglycerol binding or protein kinase C (PKC)–mediated
serine/threonine phosphorylation [9,35]. In agreement with this
idea, we observed that TPA triggered the tyrosine phosphorylation
of both endogenous and ectopically expressed Vav2 in keratino-
cytes (Figure 5F). This phosphorylation was blocked when cells
were pre-incubated with either general PKC (GF109203X) or Src
family (PP2) inhibitors (Figure 5F) prior to the TPA stimulation
step. An inactive PP2 analog (PP3) did not have such inhibitory
effect on Vav2 tyrosine phosphorylation (Figure 5F). Similar
results were obtained with the TPA-mediated stimulation of Erk
route (Figure 5G). Although many PKC family members are
present in keratinocytes (Figure S4A), we believe that a classical
PKC (cPKC) must be involved, because we could reproduce the
lack of Rac1 activation typically seen in Vav22/2;Vav32/2
keratinocytes when we incubated the wild-type counterparts with
Go¨6976 (Figure 5H), a cPKC-specific inhibitor that does not
inactivate PKCs belonging to the novel or atypical subclasses [36].
A similar effect was observed when Fyn (ID number: 14360) was
knocked down in wild-type cells using short hairpin RNA (shRNA)
techniques (Figures 5H and S4B), indicating that this kinase was
the Src family member preferentially involved in this signaling
response. This is consistent with previous results reporting the
(n= 4). In (B), sections were stained with antibodies to the cleaved fragment of caspase 3 (ID number: 12367) and 14, 49,6-diamidino-2-phenylindole
(DAPI) to reveal apoptotic cells (red color) and cell nuclei (blue color), respectively. (D, E) Example (D; scale bar, 100 mm) and quantification (E) of
phospho-histone H2AX+ keratinocytes (brown color) present in the epidermis of short-term DMBA-treated mice of indicated genotypes (n= 4). p-,
phosphorylated. (F) Number of apoptotic (annexin V+) wild-type and Vav22/2;Vav32/2 keratinocytes induced after 8 (left panel) and 12 (right panel) h
in the indicated culture conditions (n= 4). Bleo, bleomycin; DTT, dithiothreitol; NS, no statistically significant. (G, H) Example of a flow cytometry
experiment (G) and subsequent quantification (H) of the level of apoptosis induced by either DMBA (G, H) or serum starvation (H) in wild-type and
Vav22/2;Vav32/2 keratinocytes ectopically expressing GFP either alone (G, H) or in combination with HA-Vav2 (H) or Myc-Vav3 (G, H) (n= 3). In (G),
only the gated GFP+ cells are shown.
doi:10.1371/journal.pbio.1001615.g002
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Figure 3. Vav proteins play pleiotropic roles during the skin tumor promotion phase. (A) Scheme of the experiments made in this section.
(B–D) Example of immunofluorescence experiments (B; scale bar, 100 mm) and quantification of the hyperplasia (C, green color cells) and number of
BrdU+ keratinocytes (D) in the epidermis of TPA-treated mice of indicated genotypes (n= 6). In (B), sections were stained with antibodies to keratin 14
(ID number: 16664), DAPI, and rhodamine-phalloidin to reveal K14 (green color), cell nuclei (blue color), and F-actin (red color), respectively. TPA-1
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TPA-mediated stimulation of this kinase in mouse keratinocytes
[37]. These results indicate that Vav proteins act downstream of a
cPKC/Fyn signaling route that mediates the pro-mitogenic effects
of TPA in keratinocytes.
Vav Proteins Promote a Large Transcriptomal Program
During the Promotion Phase of Skin Tumors
We next considered the possibility that Vav proteins could
control, in addition to the intrinsic signaling programs of
keratinocytes described above, the stimulation of long-range
autocrine/paracrine programs in the skin. This idea was consistent
with the long-term defects seen in the activation/expression of G1/
S phase-related signaling proteins in the epidermis of TPA-
stimulated Vav2;Vav3-deficient mice (Figure 3F) and, in addition,
by the total lack of inflammatory response found in the skin of
those mice (Figure 3G–I). To explore this idea, we carried out
microarray experiments to identify the fraction of the TPA-
induced transcriptome of the skin (epidermis plus dermis) that was
Vav-dependent. We found a significant subset of TPA-regulated
transcripts whose upregulation (Figure S5A; right panel, A1
cluster; for functional annotation, see Table S3A,B) or repression
(Figure S5A; right panel, A2 cluster; for functional annotation, see
Table S3C,D) was Vav2/Vav3-dependent. Interestingly, bioinfor-
matics analyses using a skin tumor microarray dataset [38]
revealed that most A1 cluster transcripts displayed a similar up-
regulation in DMBA/TPA-induced papillomas and/or cSCCs
when compared to normal skin (Figure S5B, see clusters 2 and 3).
Conversely, most A2 cluster mRNAs were expressed in normal
skin and down-regulated in papillomas and/or cSCCs (Figure
S5B, see clusters 5 and 6). These results indicated that the short-
term Vav2/Vav3-dependent gene signature identified in the above
microarray experiments is mostly conserved in fully developed
tumors.
The functional annotation of the A1 gene cluster revealed a
statistically significant enrichment of genes encoding extracellular
ligands, including EGF family members (i.e., amphiregulin [Areg,
ID number: 11839], tumor growth factor a [TGFa, ID number:
21802], heparin-binding EGF-like growth factor [HbEGF, ID
number: 15200]), hepatocyte growth factor (HGF, ID number:
15234), fibroblast growth factor 7 (FGF7, ID number: 14178),
vascular endothelial growth factor b (VEGFb, ID number: 22340),
and a large cohort of cytokines and chemokines (i.e., IL1b [ID
number: 16176], interleukin 6 [IL6, ID number: 16193]) (Table
S4). The detection of cytokine-encoding transcripts was not due to
the infiltration of hematopoietic cells in the samples analyzed,
because the A1 cluster did not include myeloid- or lymphocyte-
specific genes (Table S3A). In silico analyses indicated that many of
the genes for those ligands could be regulated by transcriptional
factors belonging to the Stat (p= 6.461026), nuclear factor of
activated T-cells (NFAT; p= 0.002), nuclear factor kappa-light-
chain-enhancer of activated B cells (NFkB; p= 0.004), AP1
(p#0.05), and E2F (p= 0.03) families.
We confirmed by quantitative RT-PCR (qRT-PCR) that Vav
proteins were important for the TPA-mediated induction of
mRNAs for EGF family ligands, HGF, FGF7, IL6, and IL1b both
in vivo (Figure S5C) and in vitro (Figure S5D). The only exception
found for the correlation between whole skin and cultured
keratinocytes was the Tgfa mRNA, which showed a Vav-
dependent expression pattern in TPA-stimulated skin (Figure
S5C) but not in isolated primary keratinocytes (Figure S5D). These
results suggest that some of the transcripts detected in the skin
microarray experiments probably represent secondary waves of
transcriptional activation set in place upon the engagement of
other Vav2/Vav3-dependent extracellular ligands. Defects in the
production of HGF and IL6 by Vav2;Vav3-deficient mice were
confirmed at the protein level using ELISA determinations in skin
and serum samples obtained from TPA-treated animals (Figure
S6A) and, in the case of IL6, by carrying out immunohistochem-
ical analyses in skin sections (Figure S6B). The TPA-mediated up-
regulation of these Vav-dependent transcripts was abolished in
wild-type keratinocytes upon the Fyn mRNA knockdown (Figure
S7), indicating that this autocrine/paracrine program is one of the
downstream responses triggered by the TPA/cPKC/Fyn/Vav
pro-mitogenic route previously characterized in keratinocytes (see
above, Figure 5).
This Vav-dependent autocrine/paracrine program was kerati-
nocyte-specific, since it was mostly absent in the recently described
Vav-dependent transcriptome of mouse breast cancer cells [17].
Indeed, these two transcriptomes only shared the Areg, Hbegf, Tnfa,
Il24 (ID number: 93672), Il23a (ID number: 83430), Osm (ID
number: 18413), and Cxcl14 (ID number: 57266) transcripts
(Table S4). By contrast, we observed that the majority of the
Vav2/Vav3-dependent transcripts previously found to be involved
in the lung-specific metastasis of breast cancer cells was also
present in the Vav-dependent transcriptome of TPA-stimulated
skin (Inhba [ID number: 16323], Ptgs2 [ID number: 19225],
Tacstd2 [ID number: 56753]; Figure S8) [17]. The only exception
was Ilk (integrin-linked kinase, ID number: 16202), which was
repressed rather than induced by TPA independently of the
expression status of Vav proteins (Figure S8A). This indicates that
the Vav-dependent transcriptome contains both cell-type-dependent
(i.e., the autocrine/paracrine program) and -independent (i.e., lung
metastasis-related genes) subsets.
The Vav Family-Dependent Autocrine/Paracrine Program
Regulates Keratinocyte Survival and Proliferation
Given the critical roles that extracellular factors play in both the
initiation and promotion phase of skin tumors [29,30], we
investigated whether they could be involved in the tumorigenic
defects observed in Vav22/2;Vav32/2 keratinocytes. If so, we
speculated that the experimental manipulation of the extracellular
environment had to rescue wild-type-like responses in them. To
this end, we first checked whether the survival defects exhibited by
DMBA-treated keratinocytes could be overcome when co-culturing
them in the presence of equal numbers of wild-type cells. To
distinguish each cell subpopulation in the mixed cultures, one of the
subpopulation was labeled with a cell permeable chromophore prior
to the co-culturing step. Using annexin V flow cytometry, we found
that wild-type cells restored normal survival rates to both DMBA
and serum deprivation in the co-cultured Vav22/2;Vav32/2
refers to tissue samples harvested either 24 (C) or 17 (D) h after the TPA stimulation. ET, epidermal thickness. (E) Quantification of the number of
BrdU+ keratinocytes at the indicated times after a single topic application of TPA in animals of indicated genotypes (n= 3). (F) Phosphorylation and
expression status of indicated proteins in the epidermis of wild-type and Vav22/2;Vav32/2 mice at the indicated times after a single topic application
of TPA. Tubulin a (ID number: 22142) was used as loading control. WB, Western blot. (G–I) Example (G; scale bar, 100 mm) and quantification of the
neutrophil infiltration (H, green color) and edema (I) induced by TPA in mice of indicated genotypes (n= 3). In (G), the sections were stained with
antibodies to myeloperoxydase (MPO, ID number: 17523), DAPI, and rhodamine-phalloidin to decorate neutrophils (green color), nuclei (blue color),
and F-actin (red color), respectively. TST, total skin thickness.
doi:10.1371/journal.pbio.1001615.g003
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Figure 4. The defective proliferation of the epidermis of Vav22/2;Vav32/2 mice is not due to a defective hematopoietic system. (A)
Scheme of the bone marrow reconstitution experiments used to generate data in panels (B) and (C). BM, bone marrow. (B, C) Example (B; scale bar,
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keratinocytes (Figure 6A). A similar protective effect was found
when we included, without wild-type cells, ligands for trans-
membrane tyrosine kinase receptors (epidermal growth factor
[EGF, ID number: 13645], TGFa, HGF, FGF7) in the culture
media of Vav22/2;Vav32/2 keratinocytes (Figure 6B). By
contrast, the addition of IL6 protected wild type but not
Vav22/2;Vav32/2 keratinocytes in the same type of experiments
(Figure 6B).
The cell cycle defects shown by those cells under TPA-
stimulation conditions were also eliminated when the serum-free
media was supplemented with either transmembrane tyrosine
kinase receptor ligands or IL1b (Figure 6C). However, as in the
apoptotic assays, we observed that IL6 could induce cell cycle
entry in wild-type but not in Vav-deficient keratinocytes
(Figure 6C). This lack of responsiveness was not due to abnormal
expression of any of the two IL6 receptor (IL6-R) subunits (Figure
S9), indicating that Vav2;Vav3-deficient keratinocytes have, in
addition to the general defect in the generation of the autocrine/
paracrine program, a specific signaling defect downstream of the
IL6-R. Consistent with this idea, immunoblot analyses indicated
that EGF (Figure 6D), but not IL6 (Figure 6E), could trigger
proper phosphorylation levels of Erk and Stat3 in Vav22/2;Vav32/2
keratinocytes. This was a direct consequence of the Vav2;Vav3 gene
deficiency, because we could restore normal phosphorylation
levels of Erk and Stat3 downstream of the IL6-R upon the re-
expression of either HA-tagged Vav2 (Figure 6F) or Myc-tagged
Vav3 (Figure 6G) in Vav22/2;Vav32/2 cells. The implication of
Vav proteins in the signaling of the IL6-R was further
demonstrated by the observation that IL6 triggered tyrosine
phosphorylation of endogenous Vav2 in wild-type keratinocytes
(Figure 6H).
The Vav Family-Dependent Autocrine/Paracrine Program
Is Involved in the Promotion Phase of Skin Tumorigenesis
To further evaluate the relevance of the Vav-dependent
autocrine/paracrine program, we investigated whether the intra-
dermal injection of mitogens could eliminate the proliferative and
inflammatory defects seen in the skin of TPA-treated Vav22/2;
Vav32/2 mice. We observed that the injection of EGF, TGFa, or
FGF7 induced similar levels of hyperplasia (Figure 7A) and BrdU
immunoreactivity (Figure 7B) in the epidermis of wild-type and
Vav2;Vav3-deficient mice. The simultaneous application of TPA
resulted in a synergistic proliferative response in the epidermis of
animals of both genotypes (Figure 7C,D). The intradermal
injection of IL6 could trigger a robust, TPA-like mitogenic
response in the epidermis of control but not Vav22/2;Vav32/2
animals (Figure 7A–D), thus recapitulating the signaling defects
observed in primary keratinocyte cultures (see above; Figure 6).
IL6, but not the other ligands tested, did induce a potent
infiltration of neutrophils in the skin of both wild-type and
knockout mice (Figure 7E,F). This indicates that, unlike the case of
keratinocytes, the IL6-R does not require the presence of Vav2
and Vav3 for proper signaling in myeloid cells. This is not due to
functional compensation events from Vav1, because IL6-treated
Vav12/2;Vav22/2;Vav32/2 mice showed neutrophil infiltration
rates similar to both wild-type and Vav22/2;Vav32/2 animals
(Figure 7F, right panel).
Carcinomas from Vav Knockout Mice Show Exacerbated
Production of Mitogens
Finally, we investigated whether the tumors that developed in
Vav2;Vav3-deficient mice could be the result of the outgrowth of
cancer cells that, due to selection events, could have compensated
the lack of Vav proteins by the exacerbation of other signaling
routes. We suspected that such compensation could occur in this
case because the few tumors that developed in mutant mice
displayed a high similarity to those found in control animals in
terms of size distribution, proliferation rates, and differentiation
stage (unpublished data). Based on the above, we decided to
compare the abundance of transcripts encoding a variety of
mitogenic ligands in papilloma and cSCC samples obtained from
FVB mice of both genotypes. In addition, we monitored the
expression pattern in those samples of Vav2/Vav3-dependent
genes that were common between breast cancer cells and TPA-
stimulated keratinocytes [17]. We observed that the Vav2/Vav3-
dependent Tgfa, Hgf, Fgf7, and Il6 transcripts showed reduced
abundance in papillomas derived from Vav2/Vav3-deficient mice
when compared to the levels present in control mouse tumors
(Figure 8A). This reduction, however, was milder than the defect
originally seen in the TPA-stimulated skin of Vav22/2;Vav32/2
mice (see above, Figure S5C). Other Vav2/Vav3-dependent (Areg,
Hbegf) and -independent (Egf, Btc [ID number: 12223]) transcripts
displayed similar levels in papillomas regardless of the Vav2/Vav3
expression status, further suggesting that the autocrine/paracrine
defect was ameliorated in these tumors (Figure 8A). Such
compensation event was exacerbated in carcinomas, since we
observed a striking up-regulation of the abundance of EGF-R
family ligand transcripts in all cSCC samples derived from mutant
mice (Figure 8B). Such up-regulation took place irrespectively of
whether the ligands were of the Vav-dependent (Tgfa, Areg, Hbegf)
or Vav-independent (Egf, Btc) subclasses (Figure 8B). Carcinomas
from Vav2;Vav3-deficient mice also displayed up-regulation of the
Hgf mRNA (Figure 8B). This was not a sign of a total elimination
of the Vav2/Vav3 signaling deficiency, because lower levels of
Fgf7 and Il6 transcripts were still detected in cSCCs collected from
Vav22/2;Vav32/2 mice (Figure 8B). A similar behavior was
observed in the case of the Inhba and Ptgs2 when their abundance
was compared between papilloma and cSCCs (Figure 8C,D).
However, the Tacstd2 and Ilk transcripts showed no variations in
these experiments (Figure 8C,D). These results suggest that the
HRasQ61L-transformed keratinocytes have to progressively bypass
part of the Vav2/Vav3 signaling deficiency to generate fully
developed tumors. This compensation event is not due to Vav1
overexpression, because this transcript shows a similar 3-fold
increase in abundance in cSCCs of both wild-type and Vav22/2;
Vav32/2 mice (n= 4).
Discussion
Our work indicates that Vav2 and Vav3 play first- and second-
level signaling roles in keratinocytes that, although mechanistically
100 mm) and quantification (C) of the epithelial hyperplasia induced upon four daily applications of TPA in the skin of wild-type and Vav22/2;Vav32/2
C57BL/10 mice previously reconstituted with a wild-type hematopoietic system (C57BL/6-Ly5.1 genetic background) (n= 3 animals/genotype). In (B),
sections were stained with antibodies to K14, DAPI, and rhodamine-phalloidin to reveal K14 (green color), cell nuclei (blue color), and F-actin (red
color), respectively. (D) Scheme of the bone marrow reconstitution experiments used to generate data in panels (E) and (F). (E, F) Example (E; scale
bar, 100 mm) and quantification (F) of the epidermal thickness induced by four daily applications of TPA in the skin of wild-type C57BL/6-Ly5.1 mice
whose hematopoietic systems had been reconstituted with either wild-type or Vav22/2;Vav32/2 bone marrow cells (C57BL/10 genetic background)
(n= 3 animals/genotype). Panels shown in (E) were stained as in panel (B).
doi:10.1371/journal.pbio.1001615.g004
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Figure 5. Vav-dependent routes in keratinocytes. (A) Quantification by flow cytometry of the number of EdU+, S-phase cells induced by the
stimulation of quiescent keratinocytes of the indicated genotypes with either TPA or a synthetic keratinocyte growth media (CnT07). (B)
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different, act in a concerted manner to favor the initiation and
promotion phases of CSTs (Figure 8E). From a signaling
hierarchical point of view, the earliest role of Vav proteins is to
work in a cPKC- and Fyn-dependent signaling cascade that leads
to the downstream stimulation of Rac1 and optimal phosphory-
lation kinetics of both Erk and Stat3 (Figure 8E, step 1). This route
has a direct impact on the G1/S transition of primary
keratinocytes. A more distal endpoint of this Vav-dependent route
is the engagement of a wide autocrine/paracrine program that
favors keratinocyte survival to DNA damage, epithelial hyperpla-
sia, and the formation of an inflammatory microenvironment
(Figure 8E, step 2). This program is composed of extracellular
factors (i.e., HGF, FGF7, IL1b) involved in the monovalent
regulation of keratinocyte survival and proliferation during the
initiation and promotion phases, respectively. In addition, it
contains bivalent extracellular factors (i.e., IL6) that regulate
keratinocyte mitogenesis and the engagement of inflammatory
responses during the tumor promotion phase. Finally, Vav
proteins play a second-level, keratinocyte-specific role in the
signaling route of one of the Vav2/Vav3-dependent extracellular
factors, the cytokine IL6 (Figure 8E, step 3). This biological
program may play roles in both inchoate and fully established
tumors, as indicated by the similar regulation of the TPA-induced
Vav2/Vav3-dependent gene signature in papillomas and cSCCs
obtained from DMBA/TPA-treated mice. By contrast, we have
observed that the compound Vav2;Vav3 gene deficiency does not
induce any overt dysfunction in normal skin development and
homeostasis, indicating that the Vav2/Vav3-dependent route only
becomes functionally relevant in the epidermis under conditions
that require increased signaling thresholds for the assembly of new,
pathophysiological-specific programs. To our knowledge, this is
the first demonstration of the implication of Vav proteins, Rho
GEFs, or any Rho GTPase in the assembly of such large
autocrine/paracrine program in either a physiological or pro-
tumorigenic scenario.
Several indications support the idea that the upstream and
downstream roles of Vav proteins in this autocrine/paracrine
program are critical for the initiation and promotion phase of
inchoate skin tumors and, probably, for long-term tumor
sustenance. Thus, previous reports have shown that many of the
Vav2/Vav3-dependent extracellular factors regulated by Vav2
and Vav3 contribute to keratinocyte survival, proliferation, and
tumorigenesis [29,30]. Furthermore, we have shown that all the
defects detected in cultured Vav22/2;Vav32/2 keratinocytes can
be effectively bypassed upon their co-culture with wild-type
keratinocytes or, alternatively, upon the addition of specific
Vav2/Vav3-dependent ligands (EGF family ligands, HGF,
FGF7, IL1b) to their cultures. Similar results were observed when
these rescue experiments were carried out in vivo using
intradermal injections of those extracellular factors in Vav22/2;
Vav32/2 mice. However, and in good agreement with the critical
role of Vav proteins downstream of the IL6-R, IL6 could not
restore the survival and mitogenic defects of Vav2/Vav3-deficient
keratinocytes when used in vitro or in vivo. It is likely that these
second-level signaling defects also contribute to the lower tumor
burden observed in Vav22/2;Vav32/2 animals, since previous
reports have shown that IL6-mediated signaling is essential for skin
tumorigenesis [39]. Interestingly, we observed that IL6 did restore
the defective inflammatory response observed in the skin of TPA-
stimulated Vav22/2;Vav32/2 animals. This result indicates that
IL6 is indeed part of the Vav2/Vav3-dependent pro-mitogenic
and pro-inflammatory program of keratinocytes and, in addition,
that the critical role of Vav proteins downstream of the IL6-R is
keratinocyte-specific. The use of Vav12/2;Vav22/2;Vav32/2 mice
has ruled out the possibility that the normal chemoattraction of
Vav22/2;Vav32/2 neutrophils induced by IL6 could be due to
functional compensation events mediated by the hematopoietic-
specific Vav1 protein [9]. Thus, these cell-type-specific differences
could be due to the presence of other IL6-regulated Rho GEFs in
neutrophils (e.g., P-Rex1) [40] or, alternatively, reflect the
implication of Vav proteins in a proliferative/survival signaling
branch of the IL6-R that is not important for migration and the
induction of the pro-inflammatory program. Additional experi-
ments using wild-type and Vav family-deficient neutrophils will be
needed to discriminate those possibilities. Finally, the pathophys-
iological importance of this program during skin tumorigenesis is
further highlighted by our in silico analyses indicating that the
Vav2/Vav3-dependent transcriptomal signature is conserved in
fully developed tumors and, in addition, by the exacerbated up-
regulation of most transcripts for those autocrine/paracrine factors
consistently seen in cSCCs from Vav22/2;Vav32/2 mice
(Figure 8E).
We surmise that these experiments have only revealed the tip of
the iceberg of this biological program, because the Vav2/Vav3-
dependent transcriptomal signature encodes other pro-mitogenic
and pro-inflammatory factors that have not been yet analyzed. It
also contains factors with assigned roles in angiogenesis (i.e., Cyr61
[ID number: 16007], IL6, VEGFb), the polarization of the TH cell
response towards the TH1 (i.e., Ccl3 [ID number: 20302], Ccl4
[ID number: 20303], Cxcl5 [ID number: 20311], IL1b, Spp1 [ID
number: 20750], TNFa), and TH17 (i.e., Csf3 [ID number:
12985], Cxcl2 [ID number: 20310], Cxcl5, IL6, IL10 [ID
number: 16153]) subtypes or the tumor-induced ‘‘education’’ of
dermal fibroblasts (i.e., IL1b) [29,30,41–43], thus suggesting that
the engagement of the Vav2/Vav3 route in keratinocytes could
result in a widespread reprogramming of the tissue microenviron-
ment (Figure 8E). This biological program is also endowed with
multiple positive feedback mechanisms that can lead to self-
amplification and long-term signal sustenance upon its initial
engagement in keratinocytes. An obvious signaling relay is the
VavRIL6RIL6-RRVavRStat3 route, since it is known that the
stimulation of phospho-Stat3 re-feeds this autocrine loop by
activating transcriptionally the Il6 gene [44,45]. The targeted
inflammatory and stromal cells provide additional options for
Phosphorylation and expression status of Erk and Stat3 proteins in TPA-stimulated keratinocytes of indicated genotypes. (C) Rac1 (upper panel) and
RhoA (lower panel) activation levels induced by the stimulation of quiescent keratinocytes of indicated genotypes with TPA (n= 3). (D)
Phosphorylation and expression status of Erk proteins in either serum- (two upper panels) or CnT07-stimulated (two bottom panels) keratinocytes of
indicated genotypes. (E) Rac1 activation levels induced by the stimulation of quiescent keratinocytes with either serum (left panel) or CnT07 media
(right panel) (n= 3). (F) Immunoprecipitation experiments showing the tyrosine phosphorylation levels of endogenous Vav2 (top panel) and
ectopically expressed HA-Vav2 (third panel from top) in wild-type keratinocytes treated with TPA (+) in the absence (2) or the presence (+) of the
indicated drugs (n= 2). Due to problems with the detection of the endogenous proteins after blot stripping, the loading control shown in the second
panel from top was made using a parallel immunoprecipitation with the same anti-Vav2 antibody. GF, GF109203X; IP, immunoprecipitation. (G)
Western blot of total cellular extracts showing the levels of phosphorylation (top) and expression (bottom) of Erk proteins in wild-type keratinocytes
stimulated as indicated in (F) (n= 3). (H) Rac1 activation levels induced by TPA in wild-type keratinocytes under the indicated experimental conditions
(n= 3). Go, Go¨ 6976; shFyn, cells infected with a Fyn-specific shRNA.
doi:10.1371/journal.pbio.1001615.g005
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amplification and diversification of signals, since those cells
can turn on additional paracrine mechanisms that target
keratinocytes and stromal cells [41–43]. Thus, it is likely
that the initial activation of the Vav route in keratinocytes
will kindle a ‘‘butterfly effect’’ that will induce widespread
and reciprocal signaling interactions among keratinocytes,
resident stromal cells, and newcomer inflammatory and
immune cells.
Our work also sheds light on issues related to functional
redundancies with the Rho GEF family and Vav subfamily during
the initiation and promotion phases of skin tumors. On the one
hand, the cell reconstitution experiments indicate that Vav2 and
Vav3 seem to act redundantly in all the biological processes
analyzed in this work. Consistent with this idea, we have observed
that single Vav22/2 and Vav32/2 knockout mice do not show the
initiation and promotion defects found in the compound
Vav2;Vav3-deficient mice (M.M.-M. and X.R.B., unpublished
data). On the other hand, this program seems to be quite
idiosyncratic for Vav proteins as inferred by the detection of a
phenotype despite the large number of Rho GEFs that, according
to our bioinformatic array analyses, are present in normal skin,
papilloma, and cSCCs. The cancer-linked phenotype of Vav2/
Vav3-deficient mice is also quite different from that previously
reported for Tiam1-deficient mice during both tumor initiation
[4,5] and papilloma/cSCC malignant progression [4]. In this
context, the observation that subsets of Rho GEFs are differen-
tially regulated in normal skin, papilloma, and cSCCs suggests the
specific engagement of physiological- and tumor-stage-specific
Rac1-, RhoA, and Cdc42 (ID number: 12540)-dependent
programs that may contribute to both skin homeostasis and
pathophysiology. These results emphasize the importance of
extending animal-model-based genetic analysis to all Rho GEF
family members.
Our results suggest that the pharmacological targeting of Vav
proteins could be a potentially useful strategy in skin cancer.
Since our data have been generated using mice lacking Vav
proteins from the initiation stage, they could only be formally
used to establish the value of such therapies at the prevention
rather than the remediation level. However, preventive thera-
pies are interesting in this case because CSTs are known to
develop at high frequency and multiplicity in individuals with
actinic keratosis or in patients treated with some immunosup-
pressants, antifungal antibiotics, or antitumoral therapies (i.e.,
B-Raf (ID number: 109880) inhibitors) [46]. Assessing the value
of such potential therapies in the case of fully developed or
metastasized CSTs will require the generation of chemically
inducible knock-in systems. In any case, we can anticipate from
the present data that anti-Vav therapies will elicit much fewer
intrinsic side effects in the skin than those based on the
inactivation of either Tiam1 or Rac1.
Materials and Methods
Ethics Statement
All animal work has been done in accordance with protocols
approved by the Bioethics committees of both the University of
Salamanca and CSIC.
Expression of Rho GEFs Using Bioinformatic Analyses
To analyze the expression of Rho GEFs mRNAs in skin and
tumors, raw data containing samples from normal tail skin (n= 83),
papillomas (n= 60), and carcinomas (n= 68) was downloaded from
the Gene Expression Omnibus website (Accession number:
GSE21264). These data were obtained in Balmain’s laboratory
using Affymetrix Mouse Genome 430 2.0 arrays and animals
belonging to a mixed Mus musculus FVB/Mus spretus genetic
background [38]. Signal intensity values were obtained from CEL
files after RMA. Probesets corresponding to Rho/Rac GEFs were
extracted from the dataset and ANOVA analysis used to identify
Rho/Rac GEF-encoding transcripts that were differentially
expressed between normal tail, papillomas, and carcinomas (p
value ,0.01). For those genes with more than one probeset
significantly deregulated, we selected the one with the lowest p
value for graphic representation.
Analysis of mRNA Abundance
Total RNA was extracted from the indicated cells using Trizol
(Sigma) and quantitative RT-PCR performed using the Quanti-
Tect SYBR Green RT-PCR kit (Qiagen) and the iCycler machine
(Bio-Rad) or, alternatively, the Script One-Step RT-PCR kit
(BioRad) and the StepOnePlus Real-Time PCR System (Applied
BioSystems). Raw data were then analyzed using either the iCycler
iQ Optical System software (Bio-Rad) or the StepOne software
v2.1 (Applied Biosystems). We used the abundance of the
endogenous Gapdh mRNA as internal normalization control.
Primers used for transcript quantitation included 59-TTG CCC
AGA ACA AAG GAA TC-39 (forward for mouse Vav1), 59-AAG
CGC ATT AGG TCC TCG TA-39 (reverse for mouse Vav1), 59-
AAG CCT GTG TTG ACC TTC CAG-39 (forward for mouse
Vav2), 59-GTG TAA TCG ATC TCC CGG GAT-39 (reverse for
mouse Vav2), 59-GGG TAA TAG AAC AGG CAC AGC-39
(forward for mouse Vav3), 59-GCC ATT TAC TTC ACC TCT
CCA C-39 (reverse for mouse Vav3), 59-GGC AAA AAG TCA
GTC CGA CC-39 (forward for mouse Fyn, transcript variants 1
and 2), 59-AAA GCG CCA CAA ACA GTG TC-39 (reverse for
mouse Fyn, transcript variants 1 and 2), 59-TCG TGG CAA AAG
AGC TTG GA-39 (forward for mouse Fyn, transcript variant 3),
59-TAG GGT CCC AGT GTG AGA GG-39 (reverse for mouse
Fyn, transcript variant 3), 59-CGT CCG CCA TCT TGG TAG
AGA GAG CAT-39 (forward for mouse Cd3e), 59-CTA CTG
CTG TCA GGT CCA CCT CCA C-39 (reverse for mouse Cd3e),
Figure 6. Vav proteins are involved in the engagement and signaling efficiency of keratinocyte autocrine/paracrine loops. (A)
Quantification by flow cytometry of the apoptosis induced in pure (No) and genotypically mixed (Yes) cultures of wild-type and Vav22/2;Vav32/2
keratinocytes upon 12 h in complete media with DMBA or under serum-free media conditions. (B) Quantification by flow cytometry of the apoptosis
observed in wild-type and Vav22/2;Vav32/2 keratinocytes kept for 12 h with serum, without serum, or without serum plus the indicated extracellular
factors (n= 3). (C) Determination by flow cytometry of the percentage of wild-type and Vav22/2;Vav32/2 keratinocytes that have entered S phase
after 4.5 h under the indicated culture conditions (n= 3). (D–F) Phosphorylation and expression status of Erk and Stat3 in serum-starved wild-type and
Vav22/2;Vav32/2 keratinocytes stimulated with either EGF (D) or IL6 (E–G) for the indicated periods of time. In panels (F) and (G), keratinocytes were
transduced with empty and Vav-encoding lentiviruses prior to the starvation and stimulation steps as indicated in the respective panel (n= 3). (H)
Tyrosine phosphorylation levels of endogenous Vav2 (top panel) in wild-type keratinocytes treated with the indicated agents for 5 min (n= 2). Due to
problems with the detection of the endogenous proteins after blot stripping, the loading control shown in the second panel from top was made
using a parallel immunoprecipitation with the same anti-Vav2 antibody.
doi:10.1371/journal.pbio.1001615.g006
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59-ATG CTA GCG ATG CAT GAG TG-39 (forward for mouse
Tgfa), 59-CAG GGA CTT TCT TGC CTG AG-39 (reverse for
mouse Tgfa), 59-CGG TGG AAC CAA TGA GAA CT-39
(forward for mouse Areg), 59-TTT CGC TTA TGG TGG AAA
CC-39 (reverse for mouse Areg), 59-GCT GCC GTC GGT GAT
GCT GAA GC-39 (forward for mouse Hbegf), 59-GAT GAC AAG
Figure 7. The defects of Vav2/Vav3-deficient mice in the promotion phase of skin tumorigenesis have an autocrine/paracrine basis.
(A–D) Quantification of the epidermal hyperplasia (A, C) and BrdU incorporation (B, D) observed in wild-type and Vav22/2;Vav32/2 mice upon 24 (A,
C) or 17 (B, D) h after indicated treatments (n= 4). TPA and extracellular factors were applied topically and intradermally, respectively. (E–F)
Quantification of the neutrophil infiltration in wild-type (E, F), Vav22/2;Vav32/2 (E, F), and Vav12/2;Vav22/2;Vav32/2 (TKO) (F) mice upon 24 h
treatments with the indicated stimuli (n= 4). In panel (F), the right graph represents data obtained upon IL6 injections. TPA and extracellular factors
were applied topically and intradermally, respectively.
doi:10.1371/journal.pbio.1001615.g007
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AAG ACA GAC G-39 (reverse for mouse Hbegf), 59-GCA GAC
ACC ACA CCG GCA CAA-39 (forward for mouse Hgf), 59-GCA
CCA TGG CCT CGG CTT GC-39 (reverse for mouse Hgf), 59-
TTT GGA AAG AGC GAC GAC TT-39 (forward for mouse
Fgf7), 59-GGC AGG ATC CGT GTC AGT AT-39 (reverse for
mouse Fgf7), 59-CTT CCT ACC CCA ATT TCC AAT G-39
(forward for mouse Il6), 59-ATT GGA TGG TCT TGG TCC
TTA GC-39 (reverse for mouse Il6), 59-ACG GAC CCC AAA
AGA TGA AGG GCT-39 (forward for mouse Il1b), 59-GGG AAC
GTC ACA CAC CAG CAG G-39 (reverse for mouse Il1b), 59-
CGC TGC TTT GTC TAG GTT CC-39 (forward for mouse
Ereg), 59-GGG ATC GTC TTC CAT CTG AA-39 (reverse for
mouse Ereg), 59-CCC AGG CAA CGT ATC AAA GT-39
(forward for mouse Egf), 59-CCC AGG AAA GCA ATC ACA
TT-39 (reverse for mouse Egf), 59-GGA ACC TGA GGA CTC
ATC CA-39 (forward for mouse Btc), 59-TCT AGG GGT GGT
ACC TGT G-39 (reverse for mouse Btc), 59-TGC ACC ACC AAC
TGC TTA GC-39 (forward for mouse Gapdh), and 59-TCT TCT
GGG TGG CAG TGA TG-39 (reverse for mouse Gapdh). Primers
used for quantitating Inhba, Ptgs2, Tacstd2, and Ilk transcripts were
described before [17]. To calculate the number of copies of mouse
Vav family mRNAs in cell/tissue samples, the Ct values obtained
for the amplified Vav1, Vav2, and Vav3 cDNA fragments by qRT-
PCR in each sample were compared with those obtained using
serial dilutions of plasmids of known concentration containing the
Vav1 (pJLZ52) [13], Vav2 (pCCM33) [17], and Vav3 (pCCM31)
[17] cDNAs. The number of copies obtained for each transcript
was finally calculated using this titration curve and the size of each
plasmid.
Animal Studies
Single and compound Vav family knockout mice were described
elsewhere [19,23,47–49]. For long-term carcinogenesis experi-
Figure 8. Progressive upr-egulation of EGF family ligands and Vav family-dependent genes in skin tumors developed in Vav22/2;
Vav32/2 mice. (A–D) qRT-PCR experiments showing the relative abundance of indicated mRNAs in DMBA/TPA-induced papillomas (A, C) and DMBA/
DMBA-induced carcinomas (B, D) in wild-type and Vav22/2;Vav32/2 FVB mice. Values for each mRNA are given in relation to the levels seen in
samples from control mice (which were given an arbitrary value of 1) (n= 4 mice per genotype). (E) Summary of the results obtained in this work. (Left
panel) The Vav2/Vav3-dependent biological programs in the skin that favor tumor initiation and promotion. (Right panel) The above programs upon
the deletion of Vav2 and Vav3 genes. Numbered gray circles indicate the three main signaling functions of Vav proteins. The intracellular and
extracellular signaling programs are indicated on the left boxes. Intracellular and autocrine/paracrine signaling is indicated by black and gray arrows,
respectively. The oncogenic route is shown in red. Stimulation steps are shown as green stars. Defective receptor signaling is induced as a stop sign.
Normal and defective processes are shown in bold and normal font types, respectively.
doi:10.1371/journal.pbio.1001615.g008
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ments, the backs of animals of the indicated genotypes were
shaved and, 2 d later, the two-step carcinogenic DMBA/TPA
protocol initiated using a single topic application of DMBA (25 mg
diluted in 200 ml of acetone, both from Sigma). The promotion
phase consisted of biweekly applications of TPA (200 ml of a
161024 M solution in acetone, Sigma) during a 20-wk-long
period. For complete carcinogenesis, mice were treated biweekly
with 5 mg of DMBA alone in 200 ml of acetone during 20 wk. The
number, size (measured with a digital caliper), and incidence of
papilloma was determined weekly. At the end of the experiment,
animals were injected intraperitoneally with BrdU (100 mg/g body
weight, Sigma) and euthanized 1 h later.
For short-term studies of in vivo epidermal apoptosis, the dorsal
skin of mice was treated with a single application of either DMBA
(25 nmol in 200 ml of acetone) or acetone (200 ml) 2 d after
shaving. For short-term in vivo proliferation assays, the dorsal skin
of mice was treated with either one or four applications of either
TPA (6.8 nmol in 200 ml acetone) or carrier solution 2 d after
shaving. Animals were injected with BrdU and euthanized, as
indicated above. For the determination of in vivo cell cycle
transitions, animals were treated with a single topic application of
TPA and, 1 h before euthanasia, injected intraperitoneally with
BrdU. Alternatively, TPA-treated animals were euthanized and
the epithelial layer obtained to generate tissue cell extracts.
For intradermal injection of mitogens and cytokines, mice were
anesthetized and injected under the epidermal layer of their skin
with 10 ml of either the appropriate protein-containing saline
solution or the control buffer injected using a 30-gauge needle and
a Hamilton microsyringe. The concentration of ligands (Pepro-
tech) in the injection solution was 100 ng/ml. Mice were then
BrdU labeled and killed as above.
For bone marrow reconstitution experiments, 3–56106 cells of
donor bone marrow cells were injected intravenously into recipient
mice that were previously subjected to sublethal doses of
irradiation (600 rad; 1 Gy = 100 rads). In these experiments, we
used ‘‘wild-type’’ C57BL/6 Ly5.1 mice in order to distinguish the
hematopoietic populations derived from them (which express the
CD45.1 surface marker) and from the knockout C57BL/10 mice
(expressing the CD45.2 surface marker). Reconstitution experi-
ments were done in both orientations. Eight weeks after injection,
peripheral blood samples were collected from the cheek vein and
the proper reconstitution of the immune system by the injected
donor cells evaluated using flow cytometry. Surface markers used
in the cytometry experiments included an allophycocyanin-labeled
mouse monoclonal antibody to CD45.2, a biotin-labeled mouse
monoclonal antibody to mouse CD45.1, a biotin-labeled rat
monoclonal antibody to mouse CD45R/B220, a biotin-labeled rat
monoclonal antibody to mouse CD19, a phycoerytrin-labeled rat
monoclonal antibody to mouse CD11b, a phycoerytrin-labeled
hamster monoclonal antibody to mouse CD3e (all from BD
Pharmingen), a biotin-labeled hamster monoclonal antibody to
mouse TCRb, and a phycoerytrin-labeled rat monoclonal
antibody to mouse CD19 (both from eBioscience). Bone-
marrow-reconstituted animals were then subjected to topic TPA
treatments in the skin as indicated above.
Whereas the long-term carcinogenesis assays were done in
animals of both the FVB and C57BL/10 genetic backgrounds, we
selected animals of the C57BL/10 background for the short-term
studies. This facilitated comparative studies with other Vav family
knockout animals (i.e., single Vav12/2 and triple Vav12/2;Vav22/2;
Vav32/2 mice, which were all homogenized in that background) as
well as the bone marrow reconstitution experiments (which required
transplantation between genetically compatible donor and recipient
mice). At the beginning of each experimental procedure, cohorts of
6–8-wk-old animals with an even gender distribution of each
genotype subset were used.
Samples from tumors and short-term skin experiments were
processed following three independent protocols: (i) Fixed in 4%
paraformaldehyde (Sigma), (ii) cryoprotected and stored at
270uC, and (iii) snap-frozen and stored at 270uC for molecular
analyses (i.e., RNA and protein extraction).
Histochemical Analyses
Tissues were extracted, fixed in 4% paraformaldehyde (Sigma),
cut in 2–3 mm thick sections, and stained with hematoxylin/eosin.
Tumor sections were analyzed by pathologists to classify them
according to malignancy grade (benign, benign plus carcinoma in
situ, malignant) and level of differentiation (high, mild poor). In
short-term experiments, the thickness of the epidermal layer and
total skin thickness was measured in vertical cross-sections in at
least 10 different locations in each mouse to determine epidermal
hyperplasia and inflammatory response (edema), respectively.
Immunohistochemical Experiments
For standard immunohistochemical staining, paraffin-embed-
ded sections were dewaxed, microwaved in citrate buffer, blocked
with 10% nonimmune horse serum (Gibco), and incubated
overnight with the appropriate primary antibody at 4uC. After
exhaustive washing in 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, and 0.1% Tween-20 (PBST), sections
were incubated with appropriate biotin-coupled secondary anti-
bodies (all used at a 1:1,000 dilution in PBST) followed by avidin-
peroxidase (ABC Elite Kit Vector, Vector labs). Positive staining
was determined using diaminobenzidine as a substrate (DAB Kit
Vector, Vector labs) following the manufacturer’s recommenda-
tions. Sections were then counterstained with hematoxylin and
mounted. Images were captured using an Olympus BX51
microscope coupled to an Olympus DP70 digital camera. Staining
quantification was blindly assessed by two independent investiga-
tors and classified according to intensity (0–10) and estimation of
ratio of cells stained (0–1). The relative value for each section was
scored as the product of intensity6ratio given a general score
ranging from 0 to 10. For immunofluorescent staining, sections
treated as before were incubated with either a Alexa Fluor 488–
labeled goat anti-rabbit IgG antibody (Molecular Probes, 1:200
dilution) or a Cy3-conjugated goat anti-mouse IgG antibody
(Jackson Immunoresearch laboratories, Inc, 1:200 dilution),
washed, and countersatined with 49,6-diamidino-2-phenylindole
(DAPI; 2 ng/ml, Sigma) with or without rhodamine-labeled
phalloidin (Molecular Probes, 1:200 dilution). Primary antibodies
used in these experiments included rabbit polyclonal antibodies to
keratin 1, keratin 5, keratin 14, and filaggrin (Covance, 1:500
dilution in each case), rabbit polyclonal antibodies to IL6
(Genzyme, 1:100 dilution), rat monoclonal antibodies to keratin
8 (Troma1, not commercial; 1/5 dilution of the hybridoma
supernatant) and CD45 (BD Biosciences, 1:50 dilution), mouse
monoclonal antibodies to keratin 10 (Santa Cruz Biotechnology,
1:50 dilution), keratin 13 (Sigma, 1:50 dilution) and histone
H2A.X (Cell Signaling, 1:100 dilution), and a rabbit polyclonal
antibody to myeloperoxidase (Abcam, 1:250 dilution). To detect
proliferating cells, dewaxed sections were denaturalized in 2N HCl
at 37uC for 1 h, washed extensively in 0.1 M borate buffer,
blocked with 2% nonfat dry milk (Nestle´) in 0.1% Triton-PBS, and
incubated overnight with a mouse monoclonal antibody to BrdU
(BD Biosciences, 1:400 dilution). To detect apoptotic cells, we used
two different approaches. In some cases, tissue sections were
deparafinized, hydrated, digested with proteinase K (Dako) for
30 min at 37uC, and subjected to the Tunel reaction using the
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Tunel-based In Situ Cell Detection kit (Roche) as indicated by the
manufacturer’s instructions. Alternatively, tissues sections were
cryoprotected using stepwise immersions in 15%–30% sucrose-
PBS solutions, embedded in Tissue-Tek OCT (Sakura Finetek
Europe), and stored frozen at 270uC. Upon thawing, slides were
blocked as described before and incubated with a rabbit polyclonal
antibody to cleaved caspase 3 (Cell Signaling, 1:50 dilution).
Images from immunofluoresce experiments were captured using a
Leica CTR600 microscope. Quantifications of both standard and
immunoflurescence signals were done with the Metamorph-
Metaview software (Universal Imaging).
Isolation and Culture of Primary Keratinocytes
Epidermis from neonates of the indicated genotypes were
treated with 250 U/ml of dispase (Roche) overnight at 4uC and
keratinocytes prepared using CnT07 media (CELLnTEC) accord-
ing to the manufacturer’s instructions. Keratinocytes were
maintained in CnT07 media on type I collagen-precoated plates
(BD Biosciences). When genotypically mixed cultures were
utilized, the keratinocytes of one the genotypes used were labeled
in culture with a cell permeable chromophore (CellTracker green
CMFDA, Invitrogen) for 30 min according to the manufacturer’s
instructions. Labeled and nonlabeled cultures were trypsinized and
plated either as genotypically pure or mixed populations in tissue
culture plates.
Apoptotic rates in vitro were determined by flow cytometry
using the Annexin V kit (Immunostep). In vitro cell cycle
transitions were determined using the Click-iT EdU Alexa Fluor
647 Flow Cytometry Assay Kit (Invitrogen). For in vitro apoptotic
assays, exponentially growing keratinocytes of the indicated
genotypes were either serum starved in Eagle’s minimal essential
medium (EMEM, Lonza) supplemented with 0.05 mM CaCl2
(Sigma) or, alternatively, treated with 100 mM DMBA, 0.15 mM
bleomycin (Sigma), or 2 mM dithiothreitol (Sigma). Cells were
then harvested 8–24 h later and the number of apoptotic cells
determined by flow cytometry using the Annexin V kit (Immuno-
step). In apoptotic experiments using keratinocytes ectopically
expressing proteins, cells that had integrated the lentiviral particle
(GFP+) were gated away from noninfected (GFP2) cells. A similar
gating strategy (presence/absence of the CellTracker green
CMFDA chromophore) was used to characterize apoptotic rates
in genotypically mixed cell cultures. In rescue experiments with
extracellular ligands, these factors were added at the beginning of
the starvation period at a concentration of either 10 ng/ml (EGF,
TGFa, HGF, FGF7; all obtained from Peprotech) or 100 ng/ml
(IL6, Peprotech) and apoptosis quantified as above after an
overnight incubation.
For keratinocyte G1/S phase transition assays, cells were starved
for 3 h as above and then stimulated by the addition EMEM
supplemented with 0.2 mM TPA, 10 ng/ml of receptors for
transmembrane tyrosine kinases (EGF, TGFa HGF, FGF7),
10 ng/ml IL1b (Peprotech), 100 ng/ml IL6, or 8% calcium-
chelated fetal calf serum. After 4 h, cells were incubated with the
EdU reactive (Invitrogen) for 30 min, and the percentage of cells
in S phase (EdU+) determined using the Click-iT EdU Alexa Fluor
647 Flow Cytometry Assay Kit (Invitrogen).
For intracellular signaling experiments, exponentially growing
primary cells of the indicated genotypes were washed and starved
for 3 h in EMEM supplemented with 0.05 mM CaCl2. For
stimulation, we used EMEM supplemented with 0.2 mM TPA,
10 ng/ml EGF, or 100 ng/ml IL6 for the indicated periods of
time. When indicated, the pan-PKC GF109203X (5 mM, Sigma),
the classical PKD-specific Go¨6976 (3 mM, Calbiochem), and the
Src family PP2 (2 mM, Calbiochem) inhibitors were added to the
starved keratinocytes 30 min before the stimulation with TPA.
The PP3 molecule was used as negative control for the PP2
experiments (2 mM, Calbiochem).
When indicated, HA-Vav2, Myc-Vav3 with or without GFP
were expressed in wild-type (GFP) or Vav22/2;Vav32/2 (each of
the above proteins) keratinocytes using lentiviral delivery methods.
To this end, the pCCM33 [17], pCCM31 [17], or pCQS1 [21]
vectors were transfected into Lenti-X 293T cells (Clontech) using
the Lenti-X HT packaging mix (Clontech). Viral particles were
collected 48 h after transfection, concentrated using the Lenti-X
concentrator kit (Clontech), and then used to infect keratinocyctes
of the indicated genotypes during 3 consecutive days using
centrifugation at 1,5006 g in the presence of 8 mg/ml polybrene
(Sigma). As controls, we carried out infections of wild-type and
mutant keratinocytes using either the empty pLVX-IRES-Hyg or
the GFP-encoding pcDH1-MCS1-EF1-coGFP (System Bioscienc-
es) lentivirus. The shRNA-mediated knockdown of Fyn transcripts
was carried out using lentiviral particles (TRC lentiviral Mouse
Fyn shRNA; Thermo Scientific) as previously described [17]. The
TRC number and the shRNA sequence yielding the greatest
knockdown was clone number TRCN0000023382 (59-AAA CCC
AGG GCT GCC TTG GAA AAG-39). This clone was used in the
experiments presented in this work.
Protein Abundance Determinations
In the case of tissue extracts, skin samples were excised from the
euthanized animals, placed on ice-cold glass plates, the epidermis
removed with a razor blade, transferred into a lysis buffer (10 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100, 1 mM
Na3VO4, 10 mM b-glycerophosphate, and a mixture of protease
inhibitors [Cømplete, Roche]), and mechanically homogenized
using the GentleMACS dissociator (Miltenyi Biotec). In the case of
primary keratinocytes maintained in culture, cells were washed
with chilled PBS, scrapped in lysis buffer, and disrupted by
extensive vortexing (Ika). Extracts were precleared by centrifuga-
tion at 14,000 rpm for 10 min at 4uC, denatured by boiling in
SDS-PAGE sample buffer, separated electrophoretically, and
transferred onto nitrocellulose filters using the iBlot Dry Blotting
System (Invitrogen). Membranes were blocked in 2% BSA (Sigma)
in TBS-T (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1%
Tween-20) for at least 1 h and then incubated overnight with the
appropriate antibodies. Those included rabbit polyclonal antibod-
ies to phospho-Erk1/2 (residues Thr202/Tyr204; Cell Signaling,
1:1,000 dilution), total Erk1/2 (Cell Signaling, 1:1,000 dilution),
phospho-Stat3 (residue Tyr705; Cell Signaling, 1:1,000 dilution),
total Stat3 (Cell Signaling, 1:1,000 dilution), cyclin E (Abcam,
1:1,000 dilution), the Myc epitope (Upstate/Millipore, 1:1,000
dilution), Gp130 (Cell Signaling, 1:1,000 dilution), PKC and PKD
(all from Cell Signaling, 1:1,000 dilution), as well as mouse
monoclonal antibodies to a-tubulin (Calbiochem, 1:1,000 dilu-
tion), phosphotyrosine (Santa Cruz Biotechnology, dilution
1:1,000), the HA epitope (Covance, 1:1,000 dilution), and IL6-
Ra subunit (Santa Cruz Biotechnology, 1:500 dilution). Home-
made rabbit polyclonal antibodies to Vav2 and Vav3 have been
previously described [16,20,24]. After three washes with TBS-T to
eliminate the primary antibody, the membrane was incubated
with the appropriate secondary antibody (GE Healthcare, 1:5,000)
for 30 min at room temperature. Immunoreacting bands were
developed using a standard chemoluminescent method (ECL, GE
Healthcare). In the case of immunoprecipitations, keratinocyte
lysates obtained as above were incubated overnight at 4uC using
either a rabbit polyclonal antibody to Vav2 or a monoclonal
antibody to HA. Immunocomplexes were collected with Gamma-
bind G-Sepharose beads (GE Healthcare Life Biosciences),
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washed, and analyzed by immunobloting as above. ELISAs were
used to measure the amount of IL6 (IL6 Mouse ELISA Kit,
Invitrogen) and HGF (HGF Mouse ELISA kit, Abnova) according
to the manufacturer’s instructions. Absorbance at 450 nm was
measured immediately at the end of the protocol using a plate
reader (Ultraevolution, Tecan).
GTPase Activation Assays
Total cellular lysates were obtained as above, snap frozen,
thawed, quantified, and analyzed using Rac1 and RhoA G-LISA
assay kits according to the manufacturer’s instructions (Cytoskel-
eton). Absorbance at 490 nm was measured using a Ultraevolution
plate reader.
Microarray Analyses
All microarray experiments were performed by the personnel of
the Genomics and Proteomics Unit of our Institution. Total
cellular RNA was extracted from the back skin of wild-type or
knockout mice treated as described before (n= 3 for each
treatment) using the RNAeasy kit (Qiagen), quantified using
6000 Nano Chips (Agilent), and used (2.3 mg/sample) to generate
labeled cRNA probes according to the manufacturer’s instructions
(Affymetrix). Purified RNA was processed and hybridized to
Affymetrix GeneChip Mouse Gene 1.0 ST as indicated elsewhere
[17,50]. Signal intensity values were obtained from CEL files after
robust multichip average [51,52]. We performed Pavlidis template
matching analysis, in which the Pearson’s correlation coefficient is
computed between the intensities measured for each gene and the
values of an independent variable [53]. The p values to test for the
null hypothesis that the correlation is zero are provided. Corrected
p values were also calculated (Q value). For functional annotation
purposes, genes were considered differentially regulated if their Q
values were lower than 0.05. For metagenomic analysis, we used as
threshold significance values a Q#0.025 and fold change
variations relative to control skin $1.5. Graphical representation
of microarray data was generated using hierarchical clustering
analysis and the BioConductor HCLUST tool.
Further bioinformatics were used to check the expression of
Vav2/Vav3-dependent mRNAs in normal skin and skin tumors.
To that end, probesets within GSE21264 dataset corresponding to
A1 and A2 gene clusters were analyzed from differential expression
between normal tail, papillomas, and carcinomas using the
microarray database indicated above and ANOVA analysis
(p#0.01). For those genes with more than one probeset
significantly deregulated, we selected the one with the lowest p
value for representation.
The raw microarray data generated in this work have been
uploaded to the GEO database (www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token = pjcxliqugwowqfq&acc = GSE40849).
Statistics
Differences in tumor multiplicity and incidence were analyzed
by the Mann-Whitney U test and the x2 test, respectively. Other
wet lab data were processed using the Student’s t or the one tail
Mann-Whitney tests. In all cases, p values lower than 0.05 were
considered statistically significant. p values were represented in all
figures as * (when #0.05), ** (when #0.01), and *** (when
#0.001). Data obtained are given as the mean 6 the s.e.m.
Supporting Information
Figure S1 Expression of Vav family members and Rho GEFs of
the Dbl family in CSTs. (A, B) qRT-PCR determination of the
number of copies (A) and relative abundance (B) of Vav family
mRNAs in keratinocytes (A), normal skin (B), and DMBA/TPA-
induced papillomas (B) from FVB (A, B) and C57BL/10 mice (A).
In (B), values are given relative to the abundance of the indicated
transcript in the appropriate control sample (which was given an
arbitrary value of 1). au, arbitrary units. These results show that
the Vav2 and Vav3 mRNAs are expressed at much higher levels
than the Vav1 transcript in primary keratinocytes isolated from
mice of both the FVB or C57BL/10 genetic backgrounds. The
abundance of those two transcripts increased about 3-fold in
DMBA/TPA-induced papillomas and cutaneous squamous cell
caracinomas (cSCCs) when compared to normal skin. By contrast,
the Vav1 mRNA only underwent a significant increase in
abundance in cSCCs, although its overall expression levels
remained significantly lower than those for the other two Vav
family transcripts using copy number criteria. (C) Bioinformatic
analysis of the expression pattern of Rho/Rac GEF-encoding
mRNAs in skin and CSTs in the Balmain’s dataset. This dataset
was generated with Affymetrix microarrays using samples from
DMBA/TPA-induced tumors and paired normal tail skin samples
[38]. Signal log ratio abundance levels are depicted as gradients
from dark blue (lowest abundance) to dark red (highest
abundance). Sample type is indicated at the top. Clusters (C1–
C4) of similarly expressed mRNAs are indicated on the left.
Transcript names are indicated on the right, with Vav family and
Tiam1 mRNAs highlighted in red. These data indicate that, in
addition to the Vav family mRNAs and the previously described
Tiam1 transcript [4], 51 additional Rho/Rac GEFs are also
enriched in skin (cluster C1), skin and papilloma (cluster C2),
papillomas and cSCCs (cluster C3), or cSCCs (cluster C4).
(TIF)
Figure S2 Analysis of the skin of wild-type and Vav22/2;Vav32/2
mice. (A) Hematoxylin-eosin stained skin sections from newborn
mice of the indicated genotypes (top) and postnatal stages (P, left).
Scale bar, 100 mm (n= 3 mice of each genotype). WT, wild type;
DKO, double Vav22/2;Vav32/2 knockout mice. (B) Expression of
the indicated differentiation keratinocyte markers (left) in the dorsal
back skin of adult mice of the indicated genotypes (top) (n= 3 mice of
each genotype). In addition to antibodies to keratin K14 (K14),
keratin K1 (K1, ID number: 16678), and filaggrin (signals shown in
green color), sections were counterstained with 49,6-diamidino-2-
phenylindole (DAPI) and rhodamine-phalloidin to visualize cell
nuclei (blue color) and F-actin (red color), respectively. Scale bar,
100 mm. These results show that the histological structure and
differentiation process are quite similar in skin of all animals
analyzed.
(TIF)
Figure S3 Normal levels of Erk and Rac1 activation are restored
in Vav22/2;Vav32/2 keratinocytes upon the ectopic expression of
Vav family proteins. (A, B) Phosphorylation and expression status
of Erk1,2 in serum-starved wild-type and Vav22/2;Vav32/2
keratinocytes that were transduced with empty (A, B), HA-Vav2
(A), and Myc-Vav3-encoding (B) lentiviruses prior to starvation
and subsequent TPA stimulation for the indicated periods of time
(n= 3). (C) Rac1 activity levels induced by TPA in quiescent wild-
type and Vav22/2;Vav32/2 keratinocytes that were transduced
prior to the stimulation step with the indicated lentiviruses (n= 3).
(TIF)
Figure S4 Dissection of the TPA/Vav-dependent route in
keratinocytes. (A) Expression and TPA-induced activation of
indicated PKC family proteins and the protein kinase D (PKD)
substrate in total cellular lysates obtained from wild-type
keratinocytes upon a 5 min stimulation with either TPA or EGF
(top) (n= 1). MW, molecular weight. (B) qRT-PCR determination
Role of Vav Proteins in HRas-Dependent Skin Tumors
PLOS Biology | www.plosbiology.org 18 July 2013 | Volume 11 | Issue 7 | e1001615
of the abundance of the Fyn mRNA in wild-type keratinocytes that
were either mock infected or transduced with lentiviruses encoding
a Fyn-specific shRNA (n= 3). Values are given relative to the
abundance of the transcript in mock-infected cells (which was
given an arbitrary value of 1).
(TIF)
Figure S5 Vav proteins regulate the expression of a large
transcriptomal program during the promotion phase of skin
tumors. (A) Hierarchical cluster diagram of mRNAs whose
abundance changes more than 1.5-fold in a Vav2/Vav3-
independent (left panel) or -dependent (right panel) manner
between control and TPA-stimulated skin. Signal log ratio
abundance levels are depicted on a dark blue (lowest abundance)
to dark red (highest abundance) scale. Columns represent
replicates of the indicated experimental groups. (B) In silico
analysis of the expression of Vav2/Vav3-dependent genes
belonging to the A1 (top panel) and A2 (bottom panel) clusters in
normal mouse skin and in DMBA/TPA-induced mouse papillo-
mas and skin carcinomas (red). mRNA abundance is depicted as in
(A). Specific cluster expression groups are indicated at the right.
(C, D) qRT-PCR analysis showing the abundance of indicated
mRNAs in naı¨ve skin (C), TPA-stimulated skin (C), quiescent
keratinocytes (D), and TPA-stimulated keratinocytes (D) of
indicated genotypes (n= 3).
(TIF)
Figure S6 Vav proteins promote autocrine/paracrine signaling
in TPA-stimulated skin. (A) ELISA detection of HGF (top panels)
and IL6 (bottom panels) in the skin (left panels) and serum (right
panels) 24 h upon the stimulation of mice of indicated genotypes
with TPA (n= 3). (B) Immunohistochemical detection of IL6
(brown color) in the epidermis of mice of indicated genotypes after
being treated with either acetone or TPA for 24 h (n= 5).
(TIF)
Figure S7 Implication of Fyn in the keratinocyte TPA/Vav-
dependent autocrine/paracrine program. qRT-PCR-determined
abundance of indicated mRNAs in control and Fyn-knockdown
keratinocytes (both from wild-type mice) upon stimulation with
TPA for indicated periods of time (n= 3).
(TIF)
Figure S8 The expression of Vav-dependent genes of breast
cancer cells is also suppressed in the epidermis of TPA-stimulated
Vav22/2;Vav32/2 mice. (A, B) qRT-PCR analysis of the
expression of indicated genes in TPA-stimulated epidermis (A)
and keratinocytes (B) obtained from mice of indicated genotypes
(n= 3). Values are given relative to the abundance of each
indicated transcript in the control sample (which was given an
arbitrary value of 1).
(TIF)
Figure S9 The Vav2/Vav3 gene deficiency does not affect the
expression of the IL6 receptor. (A, B) qRT-PCR (A, n= 3) and
immunoblot (B; n= 2) analyses showing the abundance of
indicated IL6 receptor subunits (a [ID number: 16194],
glycoprotein 130 [Gp130, ID number: 16195]) in the epidermis
(A) and cultured keratinocytes (A, B) obtained from mice of
indicated genotypes. Il6st is the transcript for the Gp130 IL6-R
subunit.
(TIF)
Table S1 Histological analysis of skin tumors developed in FVB
mice of the indicated genotypes using the DMBA+TPA treatment.
(DOCX)
Table S2 Histological analysis of skin tumors developed in FVB
mice of the indicated genotypes using the DMBA/DMBA
treatment.
(DOCX)
Table S3 Microarray analysis of the Vav2/Vav3-dependent
transcriptome in skin.
(XLS)
Table S4 Examples of Vav2/Vav3-dependent extracellular
factors induced during the promotion phase. Genes up-regulated
or down-regulated in the skin of TPA-stimulated wild-type but not
in Vav22/2;Vav32/2 mice are shown in red and blue, respectively.
Selected genes have been included according to statistical
significance value and independently of any fold change variation
criteria.
(DOC)
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Synopsis
Vav Proteins’ Role in Skin Cancer
Robin Mejia*
Freelance Science Writer, Albany, California, United States of America
The most common form of skin cancer,
squamous cell carcinoma usually isn’t
deadly. However, neither is it benign; in
some cases it can be aggressive and spread
to other organs. And much is still not
known about the signaling pathways that
enable the formation of this kind of
cancer.
Rho GTPases, which influence gene
expression, cell proliferation, and pro-
grammed cell death, show high levels of
activity in many cancers, including skin
cancer. Researchers believe a family of
compounds called GDP/GDT exchange
factors (GEFs) are critical to Rho GTPase
activity in tumor development and main-
tenance; however, because there are so
many GEFs, determining which ones are
essential and what their exact roles are
have been open questions. In this issue of
PLOS Biology, Mauricio Menacho-Ma´r-
quez and colleagues start to provide
answers. The researchers describe studies
showing that GEFs of the Vav subfamily
play important roles in the development of
skin cancer tumors in mice.
To do this, the scientists worked with
knockout mice deficient for Vav2 and
Vav3 and also with tissue cultures that
were deficient for the two proteins. First,
using wild-type and knockout mice, the
researchers used two methods involving
powerful carcinogens to promote the
development of squamous cell carcinomas.
In one case, mice were subjected to repeat
applications of 7,12-dimethylylben[a]an-
tracene (DMBA). The knockout mice
had a 2-fold reduction in total tumors,
indicating that the knocked out genes
(Vav2 and Vav3), were important to
tumor formation. When the mice were
treated with DMBA followed by 12-O-
tetradecanoylphorbol-13-acetate (TPA),
the difference was even starker. The
knockout mice had a 5-fold lower rate of
tumors. The knockout mice showed nor-
mal skin development, suggesting that
Vav2 and Vav3 were important for cancer
formation but not necessary for normal
skin development.
Additional experiments sought to ex-
plain how the Vav proteins promote
tumors. Looking at the immediate reac-
tions to DMBA, the scientists found that
the compounds caused a 2-fold increase
in programmed cell death in the knock-
out mice. In tissue culture, deficient
keratinocytes, the main cell type of the
epidermis, also suffered higher rates of
apoptosis. This fits with the lower rates of
tumor development: if the cells die, they
can’t become cancerous. The team also
showed that TPA has a different effect on
wild-type and knockout mice; knockouts
do not have the normal proliferative and
inflammatory responses to the chemical,
indicating that Vav2 and Vav3 are
needed for these responses and subse-
quent tumor formation. Importantly, this
is seen even in mice with a normal blood
formation system, indicating that it’s the
role of Vav2 and Vav3 in the epidermis
that matters.
Further experiments demonstrated that
Vav proteins influence intrinsic signaling
programs in skin cells. Specifically, they
showed that when TPA was added to
keratinocyte cell cultures, there was re-
duced activation of proteins involved in
cell cycle progression such as extracellular-
regulated kinase (Erk), a serine/threonine
kinase, and the signal transducer and
activator of transcription (Stat3), a tran-
scription factor. The phosphorylation lev-
els of Erk and Stat3 could be rescued by
the re-expression of Vav2 or Vav3 in these
cells, indicating that those defects were a
direct consequence of the absence of these
proteins in skin cells.
Microarray experiments revealed that
Vav proteins are involved in the activation
of a large biological program composed of
extracellular factors that influence the
behavior of epithelial cells and their
neighbors, such as inflammatory and other
tumor-associated stromal cells. Co-cultur-
ing of Vav-deficient keratinocytes in the
presence of wild-type cells eliminated both
their survival and proliferative defects,
indicating that Vav proteins play a critical
role. This extracellular signaling program
was not conserved in the Vav2/Vav3-
dependent transcriptome that the same
group has described recently in mouse
breast cancer cells, supporting the idea
that this biological program is specific to
the epidermal cells. By contrast, the Vav2/
Vav3-dependent gene signature was found
conserved in fully developed tumors,
indicating that it may also play roles in
tumor maintenance and/or progression.
Taken as a whole, these experiments
indicate that Vav2 and Vav3 play impor-
tant roles in the initiation and develop-
ment of skin cancers, and that they also
promote longer-term changes in cellular
signaling that support cellular survival of
DNA damage, with increases in prolifer-
ation and the development of an inflam-
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Skin section showing the proliferative
response induced by a tumor promot-
er in the epidermis of a wild-type
mouse. Keratinocytes are shown in
green. As reported in this issue, this
reaction is severely reduced in Vav-
deficient mice. Image generated by
M. Menacho-Ma´rquez.
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matory environment that can lead to
tumor formation.
The researchers caution that these
experiments have likely identified just
‘‘the tip of the iceberg of this biological
program,’’ noting that the Vav2- and
Vav3-dependent transcriptome they
identified encodes many potentially pro-
cancerous factors that have not yet been
identified. Future experiments may dem-
onstrate even more widespread repro-
gramming of tissue microenvironment.
However, the results presented here
suggest that Vav proteins may provide
useful pharmacological targets. Once
again, more research is needed: these
studies suggest preventive therapies; fur-
ther studies will show if the Vav systems
would make useful targets for cancer
treatments.
Menacho-Ma´rquez M, Garcı´a-Escudero R,
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